Latest news for Azure Minerals Ltd (OTC:AZRMF) Stock

Azure Minerals Ltd

JP Morgan analyst Andrea Teixeira maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Overweight and raises the price target from $170 to $181.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Procter & Gamble, Raises Price Target to $181

A 31-year-old homeowner recently sparked debate on Reddit&#8217;s Bogleheads forum after <a href="https://www.benzinga.com/money/what-happens-when-you-pay-off-your-mortgage">paying off their mortgage</a> in just six years, only to be called a &#8220;dumbass&#8221; by their CPA uncle. The young homeowner, who had a 3.375% interest rate on a 30-year mortgage, sought opinions on whether their decision was financially sound.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
<li>Many are surprised by Mark Cuban&#8217;s advice for lotto winners:<a href="https://www.benzinga.com/money/mark-cubans-annuity-adv"> Cash or annuity?</a></li>
</ul>
&#8220;Paying off debt feels great and to own an asset like a house outright is a great feeling,&#8221; the homeowner wrote. &#8220;Did I waste too much money paying my house off so early and should have put it into something like VOO? Am I in a better position where I can now throw down more <a href="https://www.benzinga.com/personal-finance/24/05/38761475/retire-early-or-retire-rich-man-asks-whether-its-better-to-retire-at-40-with-125-000-a-year-or-a">money into my retirement</a> and brokerage account to invest now more than ever?&nbsp;
The community&#8217;s response was mixed. Many acknowledged the psychological benefits of being debt-free while pointing out the potential opportunity cost.
One commenter noted, &#8220;Financially suboptimal. Psychologically, could be excellent.&#8221; They added, &#8220;This dude has a paid off house; they are absolutely killing it!&#8221;
Another user shared a personal perspective: &#8220;Having always lived in fear as a child of losing our home, I too made it a priority to pay off my house as soon as possible. Intellectually, I understand that I likely would have been better off financially investing that money. Psychologically, the impact has been indescribable.&#8221;
Some responses highlighted the freedom that comes with owning a home outright. &#8220;You&#8217;re free, my dude! Your finances are presumably pretty damn easy these days. Your stress level should be quite low,&#8221; one user commented.
See Also: <a href="https://www.benzinga.com/money/200k-annuities-adv">How much money will a $200,000 annuity pay out each month? The numbers may shock you.</a>
However, others pointed out the potential financial drawbacks. One detailed analysis suggested, &#8220;Without knowing all your numbers, we can safely assume this was a decision that likely will hurt you negatively by at least a couple hundred thousand dollars.&#8221;
Ultimately, the consensus seemed to be that while the decision may not have been optimal purely financially, the peace of mind and flexibility gained could outweigh the potential lost investment returns for some individuals.
As one commenter succinctly put it, &#8220;You did great. I haven&#8217;t heard of <a href="https://www.benzinga.com/real-estate/24/07/39727958/a-massive-bubble-in-the-housing-market-has-developed-and-it-is-about-to-pop-real-estate-executive-sa">people being mortgage free</a> at 31 since my grandparents walked this earth.&#8221;
Trending: Rory McIlroy&#8217;s mansion in Florida is worth $22 million today, doubling from 2017 —<a href="https://benzinga.com/money/rory-mcilroys-florida-mansion-doubled-in-value"> here&#8217;s how to get started investing in real estate with just $100</a>
There are financial implications to paying off a mortgage in 6 years – some good and some bad.&nbsp;
Pros:
<ul>
<li>Interest savings: By paying off the mortgage early, the homeowner saved a significant amount in interest payments over the life of the loan.</li>
</ul>
<ul>
<li>Increased cash flow: Without a monthly mortgage payment, the homeowner has more disposable income to invest, save, or spend.</li>
<li>Financial security: Owning the home outright provides security and eliminates the risk of foreclosure.</li>
</ul>
Cons:
<ul>
<li>Opportunity cost: The money used to pay off the mortgage could have earned higher returns if invested in the stock market. For example, investing in an S&amp;P 500 index fund historically averages a 9.8% return, which could outperform the 3.375% mortgage interest rate.</li>
<li>Tax implications: The homeowner will lose the mortgage interest tax deduction, which could result in higher taxes.</li>
<li>Reduced liquidity: Paying off the mortgage early ties up a significant amount of money that could have been used for other purposes or emergencies. </li>
</ul>
Read Next:
<ul>
<li>Mark Cuban believes &#8220;the next wave of revenue generation is around real estate and entertainment&#8221; —<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> this new real estate fund allows you to get started with just $100.</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
</ul>

Personal Finance

31-Year-Old Pays Off Mortgage In 6 Years – But His CPA Uncle Calls It A Foolish Move: Who's Right?

<a href="https://www.ft.com/content/4aa65f0f-dcdf-4849-bd87-b81b23961fc1">https://www.ft.com/content/4aa65f0f-dcdf-4849-bd87-b81b23961fc1</a>
Diabetes device maker Embecta has hired advisers to explore a possible sale, following two years of lacklustre share price performance after the medical technology business was spun out of health tech giant Becton Dickinson. Embecta, which is the world's largest maker of disposable insulin pen needles and syringes for diabetics, tapped advisers from Centerview Partners in recent months to guide a possible sale of the business, according to two people familiar with the matter. The medtech business, which sells about 8bn syringes and needle pens annually to more than 100 countries worldwide, could be an attractive takeover target for private equity because of its low market value and similar profile to other companies that have attracted recent buyout interest, two people added. Last year, Advent International and Warburg Pincus bought injectable device manufacturer Simtra BioPharma Solutions for $4.25bn after it was spun out of healthcare conglomerate Baxter International. Baxter is also currently working on a spin-off or possible sale to private equity of its kidney care division Vantive. Embecta's share price is down nearly 70 per cent since it was spun out as a separate listed company from Becton Dickinson in April 2022. The Nasdaq-listed company was valued at $2.1bn, including debt, at market close on Friday. Sales volumes at Embecta's US business, which contributes about half the group's revenue, have been hurt by the popularity of GLP-1 drugs, such as Novo Nordisk's Ozempic, which have taken business away from conventional insulin treatments for type 2 diabetes. The people briefed on the process said a sale was not guaranteed and Embecta could remain a listed company. Embecta did not immediately respond to a request for comment. Centerview declined to comment. Devdatt Kurdikar, Embecta's chief executive, told a Bank of America investor conference in May that Ozempic had led to "delay" in patients being prescribed insulin "but not an elimination". "Insulins have been around for 100 years," said Kurdikar. "Mechanistically, we don't see insulin going away because of GLP-1." Declining margins across the business as well as the length and cost of the full separation from Becton Dickinson have also weighed on the stock, according to analysts. Embecta's adjusted net income is projected to fall 23 per cent year on year to $132mn in the 12 months to the end of September this year, while annual revenues are projected to remain broadly flat at about $1.1bn, according to analyst consensus estimates. Increasing rates of diabetes in the developing world, where insulin treatment is preferred to GLP-1s, and the possible approval by the US Food and Drug Administration of a new insulin patch pump, which can hold 300 doses of insulin at once, could spur growth at the company, Kurdikar has previously said.

Asset Sales

EMBC

Reported July 19, 2024 "Diabetes Device Maker Embecta Explores Sale Amid Slowing Profits" - Financial Times

Benchmark analyst Kurt Hallead reiterates Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Buy and maintains $42 price target.

Reiteration

Benchmark Reiterates Buy on Halliburton, Maintains $42 Price Target

<a href="https://www.youtube.com/watch?v=O2uMiR0kj5w" title="https://www.youtube.com/watch?v=O2uMiR0kj5w">https://www.youtube.com/watch?v=O2uMiR0kj5w</a>

Politics

General

LIVE: Vice President Kamala Harris delivers remarks at NCAA event at the White House — 7/22/24

WIIM

Embecta shares are trading higher following a report suggesting the company is exploring a sale.

McDonald&#8217;s Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) reportedly plans to extend its $5 meal deal across most U.S. locations to attract cost-conscious diners.
Launched on June 25, this initiative aims to entice customers who have <a target="_blank" href="https://www.benzinga.com/news/24/06/39439346/why-are-mcdonald-shares-trading-higher-friday" rel="noreferrer noopener">cut back on fast food due to inflation.</a>
Approximately 93% of McDonald&#8217;s restaurants have committed to offering the bundle beyond the initial four-week window, with some locations planning to continue through August, reported <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-07-22/mcdonald-s-to-extend-5-meal-deal-citing-customer-traffic?srnd=phx-industries&amp;sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a>.
Early results show the meal deal is successfully drawing customers back to the restaurants, per the report.
McDonald&#8217;s Chief Marketing Officer Tariq Hassan and National Field President Myra Doria noted in a memo that increasing guest counts is crucial for sustained growth.
The company is also considering extending the meal deal further and extending hours of operation to meet demand during off-peak times.
The company aims to enhance its affordability strategies for the rest of the year, addressing consumer spending limitations due to shrinking disposable incomes.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/06/39524167/mcdonalds-customers-prefer-chicken-over-plant-based-options-report" rel="noreferrer noopener">McDonald&#8217;s Customers Prefer Chicken Over Plant-Based Options: Report</a>
The company&#8217;s $5 meal deal includes a McDouble cheeseburger, small fries, four-piece chicken nuggets, and a small soft drink. The fast-food chain&#8217;s menu has seen historic price hikes of more than <a target="_blank" href="https://www.benzinga.com/news/24/06/39428015/mcdonalds-announces-5-value-meal-as-it-looks-to-win-back-customers-were-committed-to-winning-the-val" rel="noreferrer noopener">200% in some cases in the past decade.</a>
McDonald&#8217;s is set to announce its second-quarter <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">earnings on July 29. </a>The extended meal deal and other affordability measures are part of the company&#8217;s efforts to maintain customer traffic amid economic pressures.
In April, the company reported first-quarter FY24 sales growth of 4.6% year-on-year to <a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38520891/mcdonalds-bottomline-faces-the-heat-of-consumer-spending-cut-in-q1-shares-slide" rel="noreferrer noopener">$6.17 billion and an adjusted EPS of $2.70</a>.
McDonald&#8217;s stock has lost more than 12% in the last 12 months. Investors can gain exposure to the stock via Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) and Vanguard Consumer Discretionary ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VCR#NYSE">VCR</a>).
Price Action: MCD shares are trading higher by 0.33% at $258.13 at last check Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by nlinnlin on Shutterstock

Equities

Movers

Media

Select Sector SPDR-Consumer Discretionary

What's Going On With Fast-Food Giant McDonald's Shares Today?

Trading Ideas

MIRA

MIRA Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 353%

RCAT

Red Cat Secures $4.4M Non-Dilutive Financing Through Unusual Machines Divestiture To Support Development Of Drone Systems For U.S. Department Of Defense And NATO Allies

JP Morgan analyst Andrea Teixeira maintains Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) with a Neutral and lowers the price target from $8 to $7.

JP Morgan Maintains Neutral on Newell Brands, Lowers Price Target to $7

FUFU

MARA

RIOT

Shares of crypto-linked stocks are trading lower amid a drop in the price of Bitcoin.

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and maintains $115 price target.

RARE

Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $115 Price Target

Alpha Modus, Corp. ("Alpha Modus"), a technology company with a core focus on artificial intelligence in retail, today announced it has received the following two new patent awards from the United States Patent and Trademark Office: &nbsp;
<ul>
<li>U.S. Patent No. 12,039,550, titled "Method for Enhancing Customer Shopping Experience in a Retail Store," issued on July 16, 2024. 
<ul>
<li>U.S. Patent No. 12,026,731, titled "Method for Personalized Marketing and Advertising of Retail Products," issued on July 2, 2024.</li>
</ul>
</li>
</ul>

INAQ

Alpha Modus Announces Two New Patent Awards For "Method For Enhancing Customer Shopping Experience In A Retail Store," And "Method For Personalized Marketing And Advertising Of Retail Products,"

Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) with a Overweight and maintains $7 price target.

MREO

Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target

JP Morgan analyst Andrea Teixeira maintains Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Underweight and raises the price target from $123 to $135.

JP Morgan Maintains Underweight on Kimberly-Clark, Raises Price Target to $135

Mattel Shares Resume Trade

Terex shares are trading higher after the company announced the acquisition of Environmental Solutions Group from Dover for $2 billion.

JP Morgan analyst Andrea Teixeira maintains Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Overweight and lowers the price target from $23 to $22.

KVUE

JP Morgan Maintains Overweight on Kenvue, Lowers Price Target to $22

Mattel shares are trading higher following a report suggesting that L Catterton made an offer to acquire the company. Also, Hasbro is reportedly discussing a potential submission of offer.

Cantor Fitzgerald analyst Olivia Brayer maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and raises the price target from $440 to $480.

VRTX

Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $480

Nickel Miners News For The Month Of April 2024

Azure Minerals Limited (AU:AZS) has released an update. Azure Minerals Limited has issued a final director's interest notice following the departur...

Azure Minerals Announces Director Resignation Details

Azure Minerals Limited (AU:AZS) has released an update. Azure Minerals Limited has announced that Mr. Brian Thomas ceased to be a director of the c...

Azure Minerals Announces Director's Departure

Azure Minerals Limited (AU:AZS) has released an update. Azure Minerals Limited has announced the cessation of MS HUI GUO as a director of the compa...

Azure Minerals Limited Announces Director Resignation

Azure Minerals Limited (AU:AZS) has released an update. In a significant update from Azure Minerals Limited, Director Mr. Anthony Rovira has sold h...

Azure Minerals Director Sells All Shares Amid Acquisition

Azure Minerals Limited (AU:AZS) has released an update. Azure Minerals Limited has announced a significant change in director's interests, with Mr....

Azure Minerals Director Sells Entire Stake

Azure Minerals Limited (AU:AZS) has released an update. Azure Minerals Limited has reported a significant change in director's interests, specifica...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Azure Minerals Ltd

News

Latest news for Azure Minerals Ltd (OTC:AZRMF) Stock